Wall Street analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to post earnings per share of ($0.03) for the current quarter, according to Zacks. Three analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from ($0.19) to $0.26. The business is scheduled to issue its next earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($1.02) per share for the current year, with EPS estimates ranging from ($1.27) to ($0.68). For the next fiscal year, analysts expect that the company will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.56) to ($1.02). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to the consensus estimate of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%.
Shares of Adaptimmune Therapeutics stock traded down $0.12 on Tuesday, hitting $10.76. 594,791 shares of the company traded hands, compared to its average volume of 468,993. The stock has a market cap of $1.02 billion, a P/E ratio of -13.45 and a beta of 1.07. Adaptimmune Therapeutics has a 52 week low of $6.60 and a 52 week high of $14.63.
In other Adaptimmune Therapeutics news, Director Ali Behbahani purchased 12,000,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average price of $1.67 per share, for a total transaction of $20,040,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of Adaptimmune Therapeutics stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total transaction of $256,250.00. The disclosure for this sale can be found here. Insiders own 26.47% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. boosted its stake in Adaptimmune Therapeutics by 18.2% during the second quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock worth $36,005,000 after buying an additional 467,852 shares during the period. Millennium Management LLC boosted its stake in Adaptimmune Therapeutics by 83.4% during the first quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock worth $16,594,000 after buying an additional 672,046 shares during the period. BlackRock Inc. boosted its stake in Adaptimmune Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock worth $9,062,000 after buying an additional 19,765 shares during the period. Dorsey Wright & Associates purchased a new position in Adaptimmune Therapeutics during the second quarter worth $6,981,000. Finally, JPMorgan Chase & Co. boosted its stake in Adaptimmune Therapeutics by 786.0% during the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after buying an additional 164,704 shares during the period. 59.32% of the stock is owned by institutional investors.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
See Also: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.